News Focus
News Focus
icon url

EOT

10/21/25 8:37 AM

#290168 RE: 1BigDaddy #290166

Not everyone can figure out basic things so to put it simply……
-2025 isn’t over yet and is still on target with the tonnage needed to launch..
-And every Partnership Kraig signed was based on Spider Silk Production…took a while to get there, but **THINK FOR A MINUTE**….. come on, you can figure it out….

Everything is about production… the new robust BAM line is finally booming in at least 3 mega ton production facilities…


2019: Polartec MOU - FAILED

2018: "Our recombinant spider silk silkworm technology is a direct drop-in replacement for traditional silkworms and allows us to move quickly, with minimal investment, to bring new products to market" - FAILED

2018: ““We are busy preparing silkworm eggs for shipment and putting the team in place at Prodigy to hit the ground running.” - FAILED

2016-2018: Army Contract - FAILED

2016: “the Company is on schedule to produce all of the recombinant spider silk necessary to fulfill its contract with the US Government on time” - FAILED

2017: Mulberry facility in Texas - FAILED

2014-2015: "R&D .... is no longer necessary" - FAILED

2014-2015: “Scale and sale” - FAILED

2013-2015: Commercialization of Big Red - FAILED

2013-2014: Warwick Mills Partnership - FAILED

2013: SSM Industries Partnership - FAILED
icon url

arachnodude

10/21/25 8:49 AM

#290170 RE: 1BigDaddy #290166

Let’s be clear....

KBLB could’ve rushed a shipment years ago just to tick a box and call it “commercial.” But that would’ve been a public-relations win and a biotech disaster. Every hiccup, every short-term “failure,” would’ve been amplified into a long-term stigma — and the silk itself would’ve been blamed instead of the scale-up process.

Mr. T didn’t take that "novelty"-driven bait. He’s not chasing momentary validation — he’s building a continuum of proof.

“Prove commercialization” doesn’t mean one spool sold. It means a system capable of sustained, verifiable production that meets industry standards, contract demands, and repeat orders. That’s the line between a biotech experiment and a manufacturing company.

And that’s exactly what BAM-1 Alpha represents — the transition from proof of silk to proof of system.

So yes, “continuous” looks slow from the outside. But in biotech, “continuous” means uninterrupted evolution — not reckless iteration.

We’re not waiting for magic. We’re watching a company methodically position itself to clear the only hurdle that ever mattered: the ability to produce spider silk at scale, on demand, and for real markets.

Bottom Line:

You don’t “prove commercialization” with noise.
You prove it with consistency.
And consistency is exactly what’s being engineered right now.

So...

You can call yourselves “truth-sayers” all you want, but truth without context isn’t truth — it’s theater.

Every “failure” WebSlinger lists is actually a milestone along a genetic engineering curve, not a grave marker. This isn’t widget manufacturing; it’s biotech. Every iteration — Monster Silk, Dragon Silk, BAM-1 — contributed genetic data that built Alpha. That’s not failure; that’s the scientific method doing its job.

You keep saying “prove us false.”
But you’re not making factual claims — you’re making final ones.
You declare outcomes before the experiments are done.
That’s not truth-telling. That’s narrative control.


And the irony?

You say you want the company to succeed, yet you dedicate every ounce of energy to ensuring no one believes it can. That’s not “holding feet to the fire.” That’s standing on the hose while shouting that nothing’s coming out.
Bullish
Bullish